Bioequivalence describes that two medicinal products, after administration of the same molar dose, are comparable with respect to the rate and extent of active substance absorption (bioavailability). In practice, bioequivalence is the central prerequisite for a generic or an alternative dosage form to be considered therapeutically equivalent to the reference medicinal product. Bioequivalence is typically demonstrated using pharmacokinetic parameters such as AUC and Cmax in a controlled bioequivalence study.
What is compared: Bioavailability and PK parameters
In bioequivalence studies, the concentration-time profiles of the active substance in blood (or suitable matrices) are measured and pharmacokinetic parameters are derived. The following are particularly relevant for the assessment:
- AUC (Area Under the Curve): Measure of the extent of systemic exposure.
- Cmax: Maximum observed concentration as an indicator of the rate of absorption.
- Tmax: Time point of Cmax (usually descriptive, rarely of primary decision-making relevance).
The standard assessment is frequently based on the ratio of geometric means (test/reference) and the 90% confidence interval. For most active substances, the acceptance interval of 80.00% to 125.00% applies for AUC and Cmax. For active substances with a narrow therapeutic index, stricter limits may apply, while scaled approaches are possible for highly variable active substances.
In addition to statistics, clinical plausibility plays a role: differences in excipients, release profiles, or manufacturing can influence absorption. Bioequivalence is therefore closely linked to pharmaceutical quality, comparability of the dosage form, and a robust manufacturing and control concept.
Study design: Cross-over, randomization, and standardization
Bioequivalence is usually investigated in randomized 2×2 cross-over designs, because each subject receives both the test and the reference product, reducing inter-individual differences. Essential elements include randomization, a defined washout phase, and standardized conditions (e.g., fasting state or high-fat meal, depending on the labeling of the reference product).
Typical inclusion and exclusion criteria include healthy adults, stable concomitant medication, and exclusion of factors that strongly influence pharmacokinetics. For certain substances or dosage forms (e.g., topical products, inhalation products, or locally acting medicinal products), alternative study designs, pharmacodynamic endpoints, or clinical endpoints may be required.
Operationally relevant are predefined time windows for sampling, standardized meals, clear rules for concomitant medication, and measures to ensure compliance. Particularly in inpatient settings, logistics, sample handling, and documentation (e.g., investigator site files, delegation logs) must be closely managed to ensure the study remains auditable.
Analysis and typical pitfalls
Statistical analysis is frequently performed using a linear model on log-transformed PK parameters. Common practical errors include insufficient sampling time points (failure to capture the elimination phase), high drop-out rates, or uncontrolled confounding factors such as grapefruit juice, smoking, or variable meals. Analytical aspects are equally critical: bioanalysis must be validated, and sample handling as well as audit trail must ensure data integrity.
In the event of deviations from the protocol (protocol deviation), it must be assessed whether the data are still evaluable or whether exclusions must be justified. The decision criteria should be clearly described in the statistical analysis plan and the data management strategy to avoid discussions with auditors or authorities.
Another pitfall is the transfer of results to clinical practice: bioequivalence is demonstrated under controlled conditions, while real-world application is more variable. Therefore, in certain cases, additional investigations (e.g., multiple-dose designs, steady-state parameters, or studies in patient groups) are considered when pharmacologically or safety-wise justified.
Regulatory classification in the EU/Germany
In the EU, bioequivalence is assessed in the context of marketing authorization applications and variation procedures. The requirements are based, among others, on EMA guidelines on bioequivalence and bioanalysis. In Germany, depending on the product type, BfArM or PEI is responsible; as part of the authorization process, study design, analysis, quality assurance, and relevance for therapeutic interchangeability are reviewed.
For submission, study data are usually structured in an electronic Common Technical Document; this includes the study report, statistical analyses, and bioanalytical methods. Particularly for more complex products, early scientific advice can be helpful to ensure acceptance of the endpoint and design.
From a regulatory perspective, the distinction from related concepts is also important: bioequivalence concerns the PK comparison of two products, while bioavailability describes the absorption from a single product. For biosimilars, additional requirements apply, as PK/PD data are typically supplemented by clinical comparative data.
Relevance for clinical trials
From the perspective of the sponsor and CRO, bioequivalence studies are a highly standardized but operationally demanding setting: a robust study budget, clean investigator site logistics, reliable sample chains, and close monitoring are required to ensure protocol compliance and data quality. Study coordination, query management, and timely data cleaning are important to ensure deviations are detected early. Full-service CROs such as mediconomics support study planning, vendor management (e.g., central laboratory), medical writing of the study report, and regulatory communication.
Frequently asked questions (FAQ) and regulatory references
Is bioequivalence sufficient to authorize a generic?
For many systemically acting active substances, yes: if quality and bioequivalence to the reference product are demonstrated, therapeutic equivalence can be inferred. For locally acting products or complex dosage forms, additional data may be required.
Why is the acceptance interval 80–125%?
The interval is based on a statistical concept for comparability of exposure and takes into account natural variability. It is internationally established and is adjusted depending on the active substance class (e.g., narrow therapeutic index).
What is the difference between bioequivalence and bioavailability?
Bioavailability describes the absorption of an active substance from a single product, while bioequivalence assesses the comparison of two products under defined conditions. Bioequivalence therefore always requires a reference.
- EMA Guideline on the Investigation of Bioequivalence: Guideline on study design, acceptance criteria, and analysis of bioequivalence studies.
- EU Regulation 536/2014 (Clinical Trials Regulation): Framework for the authorization of clinical trials, relevant when bioequivalence is conducted as a clinical trial.
- ICH E6 (R3): Good Clinical Practice; requirements for quality management, data integrity, and documentation in the study context.